Abstract:Abstract Objective Alzheimer's disease (AD) is a degenerative disease of central nervous system with unclear pathogenesis, accounting for 60% - 70% of dementia cases. It is necessary to study the pathogenesis and therapeutic prospect of AD. LncRNAs have been found to play an important role in the development of AD. This study aims to explore the role of differentially expressed lncRNAs in AD patients' serum in the pathogenesis of AD. Methods In this study, serum microarray analysis was performed in AD patients and healthy controls to establish lncRNAs and mRNA expression profiles. The biological processes and key pathways were identified by GO analysis and KEGG pathway analysis. A protein-protein interaction network was analyzed and constructed by using String database. SH-SY5Y cells were treated with Aβ 1-42 to establish AD cell model. The expression of RP11-59J16.2 and MCM2 was detected by qRT-PCR. The mRNA binding sites and target genes of RP11-59J16.2 were predicted by bioinformatics analysis. Dual luciferase reporter gene analysis verified the targeting effect of RP11-59J16.2 on MCM2. Inhibition of RP11-59J16.2 or overexpression of MCM2, CCK-8 and flow cytometry were used to detect cell viability and apoptosis and Western Blot was used to detect the expression of p-Tau. Results Differential expression of lncRNAs and mRNAs was screened by microarray data, and high expression of RP11-59J16.2 and low expression of MCM2 were detected in serum of AD patients. GO analysis and KEGG pathway analysis revealed that G 1 /S transition of mitotic cell cycle may be involved in the development of AD. The mRNA binding sites and target genes of RP11-59J16.2 were predicted by bioinformatics analysis. Dual luciferase reporter gene analysis, qRT-PCR and Western Blot were used to verify the targeted regulation of RP11-59J16.2 on MCM2. The expression of RP11-59J16.2 was increased and that of MCM2 was decreased in SH-SY5Y cells treated with Aβ1-42. CCK-8 assay and Annexin V FITC/PI apoptosis assay kit results showed that RP11-59J16.2 could reduce cell viability, aggravate apoptosis and increase Tau phosphorylation in AD cell model by inhibiting MCM2. Conclusion Through gene microarray and bioinformatics analysis, high differentially expressed lncRNAs RP11-59J16.2 and low expressed mRNA MCM2 in AD patients were screened. By using bioinformatics prediction and dual luciferase reporter gene analysis, it was confirmed that RP11-59J16.2 could target MCM2 regulation. SH-SY5Y cells were treated with Aβ1-42 to construct AD cell model. Overexpression or inhibition of RP11-59J16.2 or MCM2, we found that RP11-59J16.2 could promote neuronal apoptosis and increase Tau phosphorylation by regulating MCM2 in vitro. Thus, RP11-59J16.2 might be a potential target molecule for the prediction, diagnosis and treatment of AD.

LncRNA RMRP accelerates autophagy-mediated neurons apoptosis through miR-3142/TRIB3 signaling axis in alzheimer's disease

Down‐regulated Expression of Microrna‐338‐5p Contributes to Neuropathology in Alzheimer's Disease

MicroRNA-139 Modulates Alzheimer's-associated Pathogenesis in SAMP8 Mice by Targeting Cannabinoid Receptor Type 2.

LncRNA RP11-59J16.2 aggravates apoptosis and increases tau phosphorylation by targeting MCM2 in AD

miRNA375-3p/rapamycin mediates the mTOR pathway by decreasing PS1, enhances microglial cell activity to regulate autophagy in Alzheimer's disease

miR-204 silencing reduces mitochondrial autophagy and ROS production in a murine AD model via the TRPML1-activated STAT3 pathway

LncRNA BACE1-AS Promotes Autophagy-Mediated Neuronal Damage Through The miR-214-3p/ATG5 Signalling Axis In Alzheimer's Disease

Loss of miR-369 Promotes Tau Phosphorylation by Targeting the Fyn and Serine/Threonine-Protein Kinase 2 Signaling Pathways in Alzheimer’s Disease Mice

LncRNA RP11-59J16.2 Aggravates Apoptosis and Increases Tau Phosphorylation via Inhibiting MCM2 On The AD SH-SY5Y Cell Model Induced By Aβ.

MiR-137-3p Mechanisms of Action and Blood-Brain Barrier Penetrating and Neuron-Targeting Lipid Nanoparticles Deliver Mir-137-3p for the Treatment of Alzheimer's Disease

TRPML1 Participates in the Progression of Alzheimer’s Disease by Regulating the PPARγ/AMPK/Mtor Signalling Pathway

TRPML1 Participates in the Progression of Alzheimer's Disease by Regulating the PPARγ/AMPK/Mtor Signalling Pathway

MiR-191-5p alleviates microglial cell injury by targeting Map3k12 (mitogen-activated protein kinase kinase kinase 12) to inhibit the MAPK (mitogen-activated protein kinase) signaling pathway in Alzheimer’s disease

Rpph1 Upregulates CDC42 Expression and Promotes Hippocampal Neuron Dendritic Spine Formation by Competing with Mir-330-5p.

Targeting lncRNA NEAT1 Hampers Alzheimer's Disease Progression

MicroRNA‐146a Represses LRP2 Translation and Leads to Cell Apoptosis in Alzheimer's Disease

Human microRNA-153-3p targets specific neuronal genes and is associated with the risk of Alzheimer's disease.

MicroRNA-16-5p/BTG2 axis affects neurological function, autophagy and apoptosis of hippocampal neurons in Alzheimer’s disease

Microrna-101a Regulates Autophagy Phenomenon Via The Mapk Pathway To Modulate Alzheimer'S-Associated Pathogenesis

MicroRNA Mir-103A-3p Targets NPAS3 to Regulate Progression of Alzheimer’s Disease

Multidimensional autophagy nano-regulator boosts Alzheimer's disease treatment by improving both extra/intraneuronal homeostasis